Decreased sensitivity of 5-HT(1D)
receptors in melancholic depression
by
Whale R, Clifford EM, Bhagwagar Z, Cowen PJ.
University Department of Psychiatry,
Oxford.
Br J Psychiatry 2001 May; 178:454-7

ABSTRACT

BACKGROUND: Brain serotonin (5-HT) function is abnormal in major depression, but the involvement of different 5-HT receptor subtypes has been little studied. The availability of selective ligands now makes it possible to test the sensitivity of 5-HT(1D) receptors in patients with depression. AIMS: The aim of the study was to use the 5-HT(1D) receptor agonist, zolmitriptan, to test the sensitivity of 5-HT(1D) receptors in patients with depression before and after treatment with selective serotonin reuptake inhibitors (SSRIs). METHOD: We measured the growth hormone response to zolmitriptan (5 mg orally) in patients with major depression before and after SSRI treatment. A matched sample of healthy subjects acted as a control group. RESULTS: The growth hormone response to zolmitriptan was blunted in patients with a melancholic depressive syndrome. SSRI treatment produced a marked reduction in zolmitriptan-induced growth hormone release. CONCLUSIONS: Patients with melancholic depression have impaired sensitivity of the post-synaptic 5-HT(1D) receptors that mediate growth hormone release. The reduction in 5-HT(1D) receptor sensitivity following SSRI treatment is probably an adaptive response to increased levels of synaptic 5-HT.

TCAs
SSRIs
5-HT1
5-HT2
5-HT3
5-HT1a
5-HT1b
Eltoprazine
Knockout mice
5-HT2c/5-HT2b
MDMA and 5-HT1a
5-HT1b and reward
5-HT1b and anxiety
Aggression and serotonin
Triptans, migraine and depression

Refs
HOME
HedWeb
Cocaine.org
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family